A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome
Cannabis & Cannabinoid Research · 2025
DOI: 10.1089/can.2024.0188 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cannabis & Cannabinoid Research, 2025. Verfasst von Daryl Efron und 8 weiteren Autor:innen. Beteiligte Einrichtung: Murdoch Children's Research Institute, Parkville, Australia. Hauptthemen laut MEDLINE: Tourette Syndrome, Medical Marijuana, Dronabinol, Cannabidiol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Introduction
Medicinal cannabis (MC) has potential therapeutic effects in Tourette Syndrome (TS), however there has been limited research in adolescent patients. This pilot study aimed to investigate the feasibility of conducting a randomized placebo-controlled crossover trial of MC in adolescents with TS.
Method
This was a phase I/II double-blind, cross-over pilot study comparing MC with matched placebo in adolescents aged 12–18 years with TS. The active medication was Δ9-tetrahydrocannabinol (THC) 10 mg/mL and CBD 15 mg/mL in peppermint-flavored medium-chain triglyceride oil. The dose titration schedule was stratified into two participant weight bands: below 50 kg (max THC 10 mg/day) or ≥50 kg (max THC 20 mg/day). Each treatment phase lasted 10 weeks, with a 4-week washout period.
Results
Ten adolescents were randomized (mean age 14.8 years, 50% male) and seven completed the full study protocol. Two adolescents discontinued due to adverse events (one on MC, one placebo) and one was lost to follow-up. The most common adverse event was dizziness (67%). There were no serious adverse events. Among actively enrolled participants, protocol adherence was excellent: study visits 100%, blood test completions 100%, and online questionnaire completion 97.6%. Medication adherence was acceptable in 63.6%. Parents reported a high degree of study design acceptability. On the Clinical Global Impression-Improvement scale, three participants were rated as much improved on MC compared with one on placebo at 10 weeks.
Discussion
The findings suggest that the study protocol is feasible and acceptable to patients with TS and their families. A fully powered study is needed to evaluate the efficacy of MC in adolescent TS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Murdoch Children's Research Institute, Parkville, Australia.
- Royal Children's Hospital, Parkville, Australia.
- Department of Paediatrics, University of Melbourne, Parkville, Australia.
- Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, Australia.
- School of Medicine, Western Sydney University, Sydney, Australia.
ORCID-Profile: Daryl Efron
Zitieren
APA
Efron, D., Taylor, K., Chan, E., Payne, J. M., Prakash, C., Lee, K. J., Cranswick, N., Lin, P. D., & Eapen, V. (2025). A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome. Cannabis & Cannabinoid Research. https://doi.org/10.1089/can.2024.0188
Vancouver
Efron D, Taylor K, Chan E, Payne JM, Prakash C, Lee KJ, et al. A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome. Cannabis & Cannabinoid Research. 2025. doi:10.1089/can.2024.0188
BibTeX
@article{Efron2025,
author = {Efron, Daryl and Taylor, Kaitlyn and Chan, Eunice and Payne, Jonathan M and Prakash, Chidambaram and Lee, Katherine J and Cranswick, Noel and Lin, Ping-I Daniel and Eapen, Valsamma},
title = {A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome},
journal = {Cannabis & Cannabinoid Research},
year = {2025},
doi = {10.1089/can.2024.0188}
}
EUVIMED